Change in number of shares and votes in Alligator Bioscience AB
During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...
Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Alligator Bioscience’s rights issue oversubscribed
Alligator Bioscience AB (publ) (“Alligator” or the “Company”) has completed the share issue with pre-emption rights for the Company’s shareh ...
Alligator carries out a fully guaranteed rights issue of approximately SEK 86m
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has today, based on the authorizatio ...
Predicted therapeutic range dose levels reached in ATOR-1017 Phase I
Lund, Sweden, October 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced additional positive interim safety data from ...
Alligator Bioscience AB (publ): Interim report January-September 2020
Encouraging clinical safety data for ATOR-1017 The Phase I study with ATOR-1017 has progressed exceptionally well and in August we presented ...
Alligator Bioscience focuses on ATOR-1017 and mitazalimab
Lund, Sweden, October 22, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the decision to focus its resources on the t ...
Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015
Lund, Sweden, September 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today updated timelines indicating 3-6 months del ...
Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study
Lund, Sweden, August 27, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today interim safety data from its ongoing clinical ...